24 results
6-K
EX-99.1
KMDA
Kamada Ltd
22 Nov 22
Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance
7:00am
to increased S&M costs associated with expanded U.S. commercial operations and increased costs associated with accelerating recruitment for the ongoing
6-K
EX-99.1
KMDA
Kamada Ltd
7 Nov 22
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
7:00am
Exhibit 99.1
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
Trial Recruitment
6-K
EX-99.1
KMDA
Kamada Ltd
17 Aug 22
Report of Foreign Private Issuer
7:00am
phase 3 trial with the opening of additional clinical sites and recruitment of patients to the study," concluded Mr. London.
Financial Highlights … ) continue the advancement of our inhaled AAT pivotal phase 3 trial with the opening of additional clinical sites and recruitment of patients
6-K
EX-99.1
KMDA
Kamada Ltd
17 May 22
Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022
7:05am
Recruitment.
Continued Expansion Activities of our U.S. Plasma Collection Capabilities; An Important Component of Our Vertical Integration.
REHOVOT
6-K
EX-99.1
y8jbc9astnfm3zf2
15 Mar 22
Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022
7:02am
6-K
EX-99.1
aw7efbzxfl dlnf
6 Aug 19
Kamada Reports Financial Results for Second Quarter and First Six Months of 2019
7:15am
6-K
EX-99.1
p547l1ywlmvz8hi1u0
7 Jun 17
Kamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease
12:00am
20-F
n69ujs7e75wmvq cfenz
26 Mar 14
Annual report (foreign)
12:00am
6-K
EX-99.1
ps9ibf9 h3oas
24 Dec 13
Current report (foreign)
12:00am